Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Corbus Pharmaceuticals Holdings, Inc. CEO to provide corporate update at Oppenheimer 34th Annual Healthcare Life Sciences Conference. The CEO will participate in one-on-one investor meetings and give a presentation on February 14, 2024, at 8:40 a.m. ET.

NORWOOD, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Oppenheimer 34^th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024.

Oppenheimer 34^th Annual Healthcare Life Sciences Conference
Format: Presentation and one-on-one investor meetings
Presentation Date: Wednesday, February 14, 2024
Presentation Time: 8:40 a.m. ET
Webcast: Click Here

Please contact your Oppenheimer sales representative to register for the conference.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

INVESTOR CONTACT:

Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
Sean.moran@corbuspharma.com

Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com

FAQ

When is the Oppenheimer 34th Annual Healthcare Life Sciences Conference?

The conference will be held virtually on February 13-14, 2024.

What is the format of the conference presentation?

The CEO will give a presentation and participate in one-on-one investor meetings.

What is the presentation date and time?

The presentation is scheduled for Wednesday, February 14, 2024, at 8:40 a.m. ET.

How can investors register for the conference?

Investors can register for the conference by contacting their Oppenheimer sales representative.

Who will be providing the corporate update at the conference?

Yuval Cohen, Ph.D., Chief Executive Officer of Corbus Pharmaceuticals Holdings, Inc., will provide the corporate update.